Employees Retirement System of Texas trimmed its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 4.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 431,719 shares of the company’s stock after selling 22,200 shares during the quarter. Employees Retirement System of Texas’ holdings in Teva Pharmaceutical Industries Limited were worth $14,342,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TEVA. KBC Group NV raised its position in shares of Teva Pharmaceutical Industries Limited by 22.7% in the first quarter. KBC Group NV now owns 50,684 shares of the company’s stock valued at $1,627,000 after purchasing an additional 9,360 shares during the period. Stifel Financial Corp raised its position in shares of Teva Pharmaceutical Industries Limited by 5.3% in the first quarter. Stifel Financial Corp now owns 807,391 shares of the company’s stock valued at $25,885,000 after purchasing an additional 40,994 shares during the period. American International Group Inc. bought a new stake in shares of Teva Pharmaceutical Industries Limited in the first quarter valued at approximately $523,000. Focused Wealth Management Inc raised its position in shares of Teva Pharmaceutical Industries Limited by 8.8% in the first quarter. Focused Wealth Management Inc now owns 31,935 shares of the company’s stock valued at $1,025,000 after purchasing an additional 2,590 shares during the period. Finally, IFM Investors Pty Ltd raised its position in shares of Teva Pharmaceutical Industries Limited by 1.2% in the first quarter. IFM Investors Pty Ltd now owns 11,690 shares of the company’s stock valued at $375,000 after purchasing an additional 134 shares during the period. Hedge funds and other institutional investors own 56.76% of the company’s stock.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded up 2.56% during midday trading on Friday, hitting $17.60. 12,963,884 shares of the stock were exchanged. The firm has a 50-day moving average of $18.13 and a 200-day moving average of $28.20. The company’s market capitalization is $17.88 billion. Teva Pharmaceutical Industries Limited has a 1-year low of $15.22 and a 1-year high of $51.51.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter in the prior year, the firm posted $1.25 EPS. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 14th. Investors of record on Tuesday, August 29th were given a $0.085 dividend. This represents a $0.34 annualized dividend and a yield of 1.93%. The ex-dividend date of this dividend was Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -15.36%.

Several analysts have recently issued reports on TEVA shares. Vetr lowered shares of Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $32.04 price target on the stock. in a research report on Monday, June 5th. BidaskClub raised shares of Teva Pharmaceutical Industries Limited from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 13th. Mizuho raised shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and boosted their price target for the company from $25.00 to $30.00 in a research report on Thursday, June 15th. Cantor Fitzgerald started coverage on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, June 15th. They issued a “neutral” rating and a $31.00 price target on the stock. Finally, Royal Bank Of Canada set a $38.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a research report on Friday, June 16th. Five equities research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $30.91.

WARNING: This story was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-teva-shares-sold-by-employees-retirement-system-of-texas/1601051.html.

Teva Pharmaceutical Industries Limited Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.